Aktis Oncology Inc. (AKTS)
AKTS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AKTS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002035832 |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issue" | 10-Q 2026-11-12 |
| Cash and burn | $68.3M cash; operating cash flow -$21.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 55,797,845 (2026-10-30). | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $79.3M, sold $3.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.9M | -$29.9M | -$26.1M | $68.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $3.4M | -$24.1M | -$20.6M | $82.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $3.2M | -$18.3M | -$24.2M | $371.6M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q3 2026 2025-09-30 | $1.6M | -$15.5M | -$15.2M | $180.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2025-06-30 | $1.6M | -$18.1M | -$16.2M | $110.2M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2025-03-31 | $1.4M | -$15.0M | -$17.5M | $58.3M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.1% |
| 1 month | -0.1% |
| 3 months | -30.1% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -48.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals Inc. | $10.60 | -0.38% | $894.1M |
| PHAR | Pharming Group N.V. ADS each representing 10 | $12.59 | -0.08% | $889.2M |
| CTY | City Therapeutics Inc. | $16.98 | -6.19% | $854.6M |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| LTGO | Latigo Biotherapeutics Inc. | $12.60 | -3.89% | $835.4M |
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
| SVRA | Savara Inc. | $4.46 | -3.77% | $985.1M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier